RxDoctor Payments Data

Cindy Mann, APRN

Nurse Practitioner · Charleston, WVNPI 1467793091

Payments from drug & device makers

$1,162in general payments, 2019–2025

Across 53 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$205
  • AbbVie$178
  • Amarin Pharma, Inc.$128
  • Aimmune Therapeutics, Inc.$125
  • Gilead$112
  • Biohaven Pharmaceuticals, Inc.$69
  • plus $344 from 11 others

What the payments were for

  • Food & beverage$1,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,162 in reported general payments places this provider in the 80th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$7,532
Medicare patients
113
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$41,756
TrulicityDulaglutide18$26,992
EliquisApixaban11$14,485
MounjaroTirzepatide11$11,523
VascepaIcosapent Ethyl15$7,770
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,873
Omeprazole109$1,521
Levothyroxine Sodium111$1,283
Albuterol Sulfate HfaAlbuterol Sulfate36$1,248
Ventolin HfaAlbuterol Sulfate21$1,150
Metoprolol Succinate80$1,097
Prednisone94$1,022
Budesonide EcBudesonide12$999
SynthroidLevothyroxine Sodium14$971
Rosuvastatin Calcium119$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$41,75630 claims
Lilly USA, LLCTrulicity, Mounjaro$56$38,51529 claims
PfizerEliquis$57$14,48511 claims
AbbVieSynthroid$178$97114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →